

## PHARMACEUTICAL 2020

TherapeuticsMD Inc.
Rank 282 of 358

The relative strengths and weaknesses of TherapeuticsMD Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of TherapeuticsMD Inc. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by $34 \%$ points.The greatest weakness of TherapeuticsMD Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 138\% points.

The company's Economic Capital Ratio, given in the ranking table, is $-61 \%$, being $98 \%$ points below the market average of $36 \%$.

| Input Variable | Value in <br> 1000 USD |
| :--- | ---: |
| Assets, Current | 208,416 |
| Cost of Goods Sold | 6,335 |
| Intangible Assets | 5,258 |
| Liabilities, Current | 53,005 |
| Liabilities, Non-Current | 203,780 |
| Other Assets | 49,803 |
| Other Compr. Net Income | 0 |
| Other Expenses | 013 |
| Other Liabilities | $-24,940$ |
| Other Net Income | 49,647 |
| Other Revenues | 2,508 |
| Property and Equipment | 19,792 |
| Research and Development | 174,113 |
| Selling, General and Administrative <br> Expense |  |


| Output Variable | Value in <br> $\mathbf{1 0 0 0}$ USD |
| :--- | ---: |
| Assets | 265,986 |
| Liabilities | 256,785 |
| Expenses | 200,852 |
| Revenues | 49,647 |
| Stockholders Equity | 9,201 |
| Net Income | $-176,145$ |
| Comprehensive Net Income | $-176,145$ |
| Economic Capital Ratio | $-61 \%$ |

